FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287378003> ?p ?o ?g. }

• W4287378003 endingPage "791" @default.
• W4287378003 startingPage "784" @default.
• W4287378003 abstract "This study aims at constructing a staging system incorporating tumor regression grade and ypN-category (TRG-N) in patients with neoadjuvant therapy before esophagectomy. It is hypothesized that this would prognosticate better than the current American Joint Committee on Cancer (AJCC) postneoadjuvant therapy (ypTNM) stage groups.Conventional pathological T-category is defined by the depth of invasion, and may lose prognostic relevance after neoadjuvant therapy. TRG defines treatment response by the degree of tumor regression, and when combined with ypN-category may be more prognostic than AJCC postneoadjuvant therapy (ypTNM) stage groups.A training cohort of 210 patients with esophageal squamous cell carcinoma and who had had neoadjuvant therapy before esophagectomy were studied. A validation cohort comprised 107 patients from another hospital. Resected esophagi were assessed by ypT-category and TRG, the latter assigned according to the Becker 4-tier system. These categories were grouped with ypN-category into a TRG-N system. Patients' survival was compared between the current AJCC postneoadjuvant therapy (ypTNM) stage groups and this TRG-N system.In the training cohort, 5-year survival rates according to ypTNM stage I, II, IIIA, IIIB, and IVA were 53%, 39.4%, 47%, 18.3%, and 0%, respectively. For TRG-N stages I, II, III, and IV, the respective figures were 59.6%, 43.5%, 23.8%, and 15.6%. TRG-N stage showed better fit in survival than ypTNM stage groups, indicated by lower Akaike Information Criteria (AIC) and Bayesian Information Criterion values. Similar results were found in the validation cohort. Multivariate analysis showed that TRG-N stage ( P =0.02), age ( P =0.006), and sex ( P =0.005) were independent prognostic factors.TRG-N stage shows better prognostication than the AJCC postneoadjuvant therapy (ypTNM) stage groups." @default.
• W4287378003 created "2022-07-25" @default.
• W4287378003 creator A5000408412 @default.
• W4287378003 creator A5013938554 @default.
• W4287378003 creator A5015111047 @default.
• W4287378003 creator A5029677690 @default.
• W4287378003 creator A5048267225 @default.
• W4287378003 creator A5073412829 @default.
• W4287378003 creator A5080743533 @default.
• W4287378003 creator A5083454533 @default.
• W4287378003 date "2022-07-25" @default.
• W4287378003 modified "2023-10-06" @default.
• W4287378003 title "A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma" @default.
• W4287378003 cites W1977468182 @default.
• W4287378003 cites W2001748231 @default.
• W4287378003 cites W2026613554 @default.
• W4287378003 cites W2042213428 @default.
• W4287378003 cites W2058589751 @default.
• W4287378003 cites W2059562809 @default.
• W4287378003 cites W2070555748 @default.
• W4287378003 cites W2070655665 @default.
• W4287378003 cites W2086678312 @default.
• W4287378003 cites W2320015754 @default.
• W4287378003 cites W2328845621 @default.
• W4287378003 cites W2335828178 @default.
• W4287378003 cites W2337728056 @default.
• W4287378003 cites W2432764947 @default.
• W4287378003 cites W2560744893 @default.
• W4287378003 cites W2573828356 @default.
• W4287378003 cites W2787614032 @default.
• W4287378003 cites W2902711301 @default.
• W4287378003 cites W2944550252 @default.
• W4287378003 cites W3009271343 @default.
• W4287378003 cites W3022607119 @default.
• W4287378003 cites W3025148811 @default.
• W4287378003 cites W3081219804 @default.
• W4287378003 cites W3101702340 @default.
• W4287378003 cites W3154319436 @default.
• W4287378003 cites W3161014935 @default.
• W4287378003 cites W3184334354 @default.
• W4287378003 cites W4206642900 @default.
• W4287378003 doi "https://doi.org/10.1097/sla.0000000000005636" @default.
• W4287378003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35876374" @default.
• W4287378003 hasPublicationYear "2022" @default.
• W4287378003 type Work @default.
• W4287378003 citedByCount "3" @default.
• W4287378003 countsByYear W42873780032023 @default.
• W4287378003 crossrefType "journal-article" @default.
• W4287378003 hasAuthorship W4287378003A5000408412 @default.
• W4287378003 hasAuthorship W4287378003A5013938554 @default.
• W4287378003 hasAuthorship W4287378003A5015111047 @default.
• W4287378003 hasAuthorship W4287378003A5029677690 @default.
• W4287378003 hasAuthorship W4287378003A5048267225 @default.
• W4287378003 hasAuthorship W4287378003A5073412829 @default.
• W4287378003 hasAuthorship W4287378003A5080743533 @default.
• W4287378003 hasAuthorship W4287378003A5083454533 @default.
• W4287378003 hasConcept C121608353 @default.
• W4287378003 hasConcept C126322002 @default.
• W4287378003 hasConcept C143998085 @default.
• W4287378003 hasConcept C146357865 @default.
• W4287378003 hasConcept C151730666 @default.
• W4287378003 hasConcept C2777297899 @default.
• W4287378003 hasConcept C2777546739 @default.
• W4287378003 hasConcept C2777982462 @default.
• W4287378003 hasConcept C2778292576 @default.
• W4287378003 hasConcept C2779660593 @default.
• W4287378003 hasConcept C2779742542 @default.
• W4287378003 hasConcept C2780091936 @default.
• W4287378003 hasConcept C2780849966 @default.
• W4287378003 hasConcept C2993415550 @default.
• W4287378003 hasConcept C38180746 @default.
• W4287378003 hasConcept C509974204 @default.
• W4287378003 hasConcept C530470458 @default.
• W4287378003 hasConcept C71924100 @default.
• W4287378003 hasConcept C72563966 @default.
• W4287378003 hasConcept C86803240 @default.
• W4287378003 hasConceptScore W4287378003C121608353 @default.
• W4287378003 hasConceptScore W4287378003C126322002 @default.
• W4287378003 hasConceptScore W4287378003C143998085 @default.
• W4287378003 hasConceptScore W4287378003C146357865 @default.
• W4287378003 hasConceptScore W4287378003C151730666 @default.
• W4287378003 hasConceptScore W4287378003C2777297899 @default.
• W4287378003 hasConceptScore W4287378003C2777546739 @default.
• W4287378003 hasConceptScore W4287378003C2777982462 @default.
• W4287378003 hasConceptScore W4287378003C2778292576 @default.
• W4287378003 hasConceptScore W4287378003C2779660593 @default.
• W4287378003 hasConceptScore W4287378003C2779742542 @default.
• W4287378003 hasConceptScore W4287378003C2780091936 @default.
• W4287378003 hasConceptScore W4287378003C2780849966 @default.
• W4287378003 hasConceptScore W4287378003C2993415550 @default.
• W4287378003 hasConceptScore W4287378003C38180746 @default.
• W4287378003 hasConceptScore W4287378003C509974204 @default.
• W4287378003 hasConceptScore W4287378003C530470458 @default.
• W4287378003 hasConceptScore W4287378003C71924100 @default.
• W4287378003 hasConceptScore W4287378003C72563966 @default.
• W4287378003 hasConceptScore W4287378003C86803240 @default.
• W4287378003 hasIssue "5" @default.
• W4287378003 hasLocation W42873780031 @default.

• next